Molecular pathogenesis of multiple myeloma

International Journal of Clinical Oncology

Volumn 20, Issue 3, 2015, Pages 413-422

  Furukawa, Yusuke ^a   Kikuchi, Jiro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Branching evolution; Drug resistance; Genetic architecture; Intra clonal heterogeneity; Linear clonal evolution

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

CANCER GROWTH; CELL CLONE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL HETEROGENEITY; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; FUSION GENE; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; MEMORY CELL; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; PLASMA CELL; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC HYPERMUTATION; DISEASE COURSE; GENETICS; MONOCLONAL IMMUNOGLOBULINEMIA; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

DISEASE PROGRESSION; HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS;

EID: 84930573104     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0837-0     Document Type: Review

References (60)

1. Palumbo A, Anderson K (2011) Multiple myelomas. N Engl J Med 364:1046–1060
2. Mitsiades CS, Davies FE, Laubach JP et al (2011) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 29:1916–1923
3. Corre J, Munshi N, Avet-Loiseau H (2015) Genetics of multiple myeloma: another heterogeneity level? Blood 125:1870–1876
4. Gay F, Larocca A, Wijermans P et al (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117:3025–3031
5. Bringhen S, Mateos MV, Zweegman S et al (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 98:980–987
6. Sonneveld P, Goldschmidt H, Rosiñol L et al (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31:3279–3287
7. Kumar SK, Dispenzieri A, Lacy MQ et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122–1128
8. Weiss BM, Abadie J, Verma P et al (2009) A monoclonal precedes multiple myeloma in most patients. Blood 113:5418–5422
9. Agarwal A, Ghobrial IM (2013) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 19:985–994
10. Hideshima T, Mitsiades C, Tonon G et al (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585–598
11. Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519–2526
12. Noborio-Hatano K, Kikuchi J, Takatoku M et al (2009) Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 28:231–242
13. Kikuchi J, Koyama D, Mukai HY et al (2014) Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. Int J Hematol 99:726–736
14. Nutt SL, Taubenheim N, Hasbold J et al (2011) The genetic network controlling plasma cell differentiation. Semin Immunol 23:341–349
15. Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131:959–971
16. Walker BA, Wardell CP, Johnson DC et al (2013) Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121:3413–3419
17. González D, van der Burg M, García-Sanz R et al (2007) Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110:3112–3121
18. Chesi M, Nardini E, Brents LA et al (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260–264
19. Chesi M, Nardini E, Lim RSC et al (1998) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025–3034
20. Iida S, Rao PH, Butler M et al (1997) Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226–230
21. Chesi M, Bergsagel PL, Brents LA et al (1996) Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674–681
22. Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296–303
23. Lauring J, Abukhdeir AM, Konishi H et al (2008) The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 111:856–864
24. Martinez-Garcia E, Popovic R, Min D-J et al (2011) The MMSET histone methyltransferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117:211–220
25. Pei H, Zhang L, Luo K et al (2011) MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470:124–128
26. Hurt EM, Wiestner A, Rosenwald A et al (2004) Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191–199
27. Chesi M, Bergsagel PL, Shonukan OO et al (1998) Frequent dysregulation of the c-maf protooncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457–4463
28. Sawyer JR, Waldron JA, Jagannath S et al (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 182:41–49
29. Laï JL, Zandecki M, Mary JY et al (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85:2490–2497
30. Calasanz MJ, Cigudosa JC, Odero MD et al (1997) Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosom Cancer 18:84–93
31. Smadja NV, Bastard C, Brigaudeau C et al (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229–2238
32. Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471:467–472
33. Lohr JG, Stojanov P, Carter LS et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25:91–101
34. Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421
35. Bolli N, Avet-Loiseau H, Wedge DC et al (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997. doi:10.1038/ncomms3997
36. Delmore JE, Issa GC, Lemieux ME et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904–917
37. Loven J, Hoke HA, Lin CY et al (2013) Selective inhibition of tumor oncogenesis by disruption of super-enhances. Cell 153:320–334
38. Chiecchio L, Dagrada GP, Ibrahim AH et al (2009) Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 94:1708–1713
39. Annunziata CM, Davis RE, Demchenko Y et al (2007) Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115–130
40. Demchenko YN, Glebov OK, Zingone A et al (2010) Classical and/or alternative NF-κB pathway activation in multiple myeloma. Blood 115:3541–3552
41. Sawyer JR, Tian E, Heuck CJ et al (2014) Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood 123:2504–2512
42. Affer M, Chesi M, Chen WD et al (2014) Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28:1725–1735
43. Walker BA, Wargell CP, Brioli A et al (2014) Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 4:e191
44. Avet-Loiseau H, Attal M, Campion L et al (2012) Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30:1949–1952
45. Rajkumar SV, Gupta V, Fonseca R et al (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738–1744
46. Hebraud B, Leleu X, Lauwers-Cances V et al (2014) Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 28:675–679
47. Walker BA, Wardell CP, Melchor L et al (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28:384–390
48. Egan JB, Shi C-X, Tembe W et al (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120:1060–1066
49. Keats JJ, Chesi M, Egan JB et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067–1076
50. Walker BA, Wardell CP, Melchor L et al (2012) Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 120:1077–1086
51. Bahlis NJ (2012) Darwinian evolution and tiding clones in multiple myeloma. Blood 120:927–928
52. Hébraud B, Caillot D, Corre J et al (2013) The translocation t(4;14) can be present only in minor subclones in multiple myeloma. Clin Cancer Res 19:4634–4637
53. Magrangeas F, Avet-Loiseau H, Gouraud W et al (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:473–481
54. Rajkumar SV (2012) Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 87:79–88
55. Mikhael JR, Dingli D, Roy V et al (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 88:360–376
56. Boyd KD, Ross FM, Chiecchio L et al (2012) A novel prognostic model in myeloma based on co-segregation adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26:349–355
57. Mateos MV, Martinez-Lopez J, Hernandez MT et al (2014) Comparison of sequential vs alternating administration of bortezomib, melphalan, prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM): GEM2010MAS65 trial. In: Burns LJ (ed) 56th ASH Annual Meeting. American Society of Hematology, Washington DC, Abstract #178
58. Mateos MV, Hernandez MT, Giraldo P et al (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438–481
59. Ghobrial IM, Landgren O (2014) How I treat smoldering multiple myeloma. Blood 124:3380–3388
60. Pineda-Roman M, Bolejack V, Arzoumanian V et al (2007) Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 136:393–399